Inclusion Criteria:

          -  Histologically confirmed diagnosis of prostate adenocarcinoma

          -  PSA ≥ 10 ng/ml and two of the following 4 criteria:

          -  PSA ≥ 20 ng/ml,

          -  Gleason sum ≥ 8,

          -  cN1 (regional LN with a short axis length >10mm by CT scan or MRI) or pathologically
             confirmed lymph nodes (pN1),

          -  cT3-T4 (by MRI or core biopsy) (i.e. If PSA≥ 20 ng/ml then only one of the other 3
             risk factors is needed)

          -  M0 by standard imaging work-up (see chapter 6.1.1.1)

          -  Testosterone ≥ 200 ng/dl

          -  Adequate renal function: calculated creatinine clearance ≥ 50 mL/min (Appendix D)
             Magnesium and potassium within normal limits of the institution or corrected to within
             normal limits prior to the first dose of treatment.

          -  Patients with prolonged QT-intervals due to prescribed Class IA (quinidine,
             procainamide) or Class III (amiodarone, sotalol) antiarrhythmic medication must be
             carefully evaluated for GnRH-agonist or GnRH antagonist use, because these drugs may
             prolong the QT-interval.

          -  WHO Performance status 0-1

          -  Age ≥ 18 and ≤ 80 years

          -  Participants who have partners of childbearing potential must use adequate birth
             control measures, as defined by the investigator, during the study treatment period
             and for at least 3 months after last dose of study treatment. A highly effective
             method of birth control is defined as those which result in low failure rate (i.e.
             less than 1% per year) when used consistently and correctly

          -  Before patient registration/randomization, written informed consent must be given
             according to ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Previous use of androgen deprivation therapy (ADT), antiandrogens. 5-alpha reductase
             inhibitors are allowed if interrupted for more than 6 months prior to entering the
             study

          -  History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or
             angioedema.

          -  Hypersensitivity towards the investigational drug

          -  The following biological parameters :AST, ALT, total bilirubin, prothrombin time,
             serum albumin above upper level of normal range No severe hepatic impairment (Child
             Pugh C)

          -  History of gastro-intestinal disorders (medical disorder or extensive surgery) that
             may interfere with the absorption of the protocol treatment.

          -  History of pituitary or adrenal dysfunction

          -  Uncontrolled diabetes mellitus

          -  History of ulcerative colitis, Crohn's Disease, ataxia, telangiectasia, systemic lupus
             erythematous, or Fanconi anemia.

          -  Clinically significant heart disease as evidence myocardial infarction, or arterial
             thrombotic events in the past 6 months, severe or unstable angina, or New York Heart
             Association (NYHA) class III or IV heart disease or cardiac ejection fraction
             measurement of < 50 % at baseline

          -  Coronary revascularization (PCI or multivessel CABG), carotid artery or iliofemoral
             artery revascularization (percutaneous or surgical procedure) within the last 30 days
             prior to entering the trial

          -  Certain risk factors for abnormal heart rhythms/QT prolongation: torsade de pointes
             ventricular arrhythmias (e.g, heart failure, hypokalemia, or a family history of a
             long QT syndrome), a QT or corrected QT (QTc) interval >450 ms at baseline, or intake
             of medications that prolong the QT/QTc interval

          -  Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg); patients
             with a history of hypertension are allowed provided blood pressure is controlled by
             anti-hypertensive treatment.

          -  Prior history of malignancies other than prostate adenocarcinoma (except patients with
             basal cell, squamous cell carcinoma of the skin), or the patient has been free of
             malignancy for a period of 3 years prior to first dose of study drug(s). Prior history
             of bladder cancer excludes the patient.

          -  Prior radical prostatectomy (TURP or suprapubic adenomectomy for benign prostatic
             hyperplasia is allowed)

          -  Prior brachytherapy or other radiotherapy that would result in an overlap of
             radiotherapy fields

          -  Any contraindication to external beam radiotherapy

          -  Patients with significantly altered mental status prohibiting the understanding of the
             study or with psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule or any
             condition which, in the opinion of the investigator, would preclude participation in
             this trial